Bio-Reference Laboratories News and Activities

Bio-Reference Laboratories is owned by Opko Health.

Opko Health is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Opko Health is a company listed under the stock ticker OPK (US).

Opko Health has a direct presence in 2 countries.

Opko Health has 4 subsidiaries including Bio-Reference Laboratories, Eirgen Pharma and ModeX Therapeutics.

They are in:

• Pharmaceuticals40%
• Healthcare40%
• Other20%

View the org chart displaying its 8 main executives

Most searched biographies at Bio-Reference Laboratories

• Craig Allen, President and Chief Executive Officer
• Muhammad Qazi, Chief Medical Officer and Executive Vice President,...
• Scott Montgomery, Senior Vice President, Chief Commercial Officer

Create your alert
to follow the executive moves at Bio-Reference Laboratories.

Opko Health has 3,493 competitors including UnitedHealth Group (United States (USA)), Kaiser Permanente (United States (USA)) and HCA (United States (USA)).

Popular M&A news in Healthcare

• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
• Freeman Health System has acquired Northwest Health (posted on June 2 2026).
• Garner Health has just announced a $100 Million fundraising (posted on May 29 2026).

Popular contacts in Healthcare

• Ari Bousbib - Chairman and Chief Executive Officer at IQVIA
• Gregory Adams - Chief Executive Officer and Chairman of the Board at Kaiser Permanente
• Pablo Legorreta - Chairman of the Board, Founder and Chief Executive Officer at Royalty Pharma

Learn more about the Healthcare industry

Press releases by Bio-Reference Laboratories

• OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies
• BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform
• OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China
• OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
• OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas
• OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19
• OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results
• OPKO Health to Participate in the Jefferies Biotech on the Beach Summit
• Press Releases
• OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
• View more press releases Close

Social media about Bio-Reference Laboratories

• Bio-Reference Laboratories on Wikipedia, Google News & Yahoo Finance
• Bio-Reference Laboratories on LinkedIn, X (Twitter) & YouTube